 Connection
Christopher Porter to T-Lymphocytes
This is a "connection" page, showing publications Christopher Porter has written about T-Lymphocytes.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.246 |
|
|
|
-
Lin HK, Blake DA, Freeman R, Chen Y, Kim J, Johnson AM, Wells K, Mudigonda A, Liu W, Yadav P, Zeng F, Muhuri A, Min K, Sarkar S, Wang Y, Goyal S, Roberts RC, Christensen E, Ward AB, Heller B, Chun P, Dougan J, Porter CC, Barwick BG, Paulos CM, Yang L, Patgiri A, Thomas SN, Waller EK, Rafiq S. Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models. Sci Transl Med. 2026 Jul 22; 18(859):eadt9565.
Score: 0.134
-
Do P, Perdue LA, Chyong A, Hunter R, Dougan J, Henry CJ, Porter CC, Dreaden EC. Rapid Assembly and Screening of Multivalent Immune Cell-Redirecting Therapies for Leukemia. ACS Comb Sci. 2020 10 12; 22(10):533-541.
Score: 0.089
-
Zoine JT, Prince C, Story JY, Branella GM, Lytle AM, Fedanov A, Alexander JS, Porter CC, Doering CB, Spencer HT, Chandrakasan S. Thrombopoietin-based CAR-T cells demonstrate in vitro and in vivo cytotoxicity to MPL positive acute myelogenous leukemia and hematopoietic stem cells. Gene Ther. 2022 05; 29(5):1-12.
Score: 0.024
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|